#Canada #Calgary #Innocan Pharma #Tamar Innovest #Debenture

Innocan Pharma's Recent Financing Initiative

Innocan Pharma Corporation has recently finalized a pivotal financing arrangement with its largest shareholder, Tamar Innovest Ltd. This strategic move involved the closing of a debenture offering, which has raised gross proceeds of $450,000. The debenture, reflective of Innocan's ambitious growth plans, is set to provide essential funds aimed at bolstering operational capabilities and seeking a listing on the New York Stock Exchange (NYSE).

Key Details of the Debenture Offering

The debenture carries an interest rate of 10% per annum and will mature in either 12 months from the issuance date or upon the completion of a public offering in the United States as outlined in the company’s registration statement with the U.S. Securities and Exchange Commission. This dual timeline ensures that Innocan has the flexibility it needs during this critical period in its growth trajectory.

The funds generated through this debenture are earmarked for working capital, alongside associated costs needed for the NYSE listing and other general corporate purposes. Iris Bincovich, the CEO of Innocan, expressed her enthusiasm regarding this investment, stating that it strengthens the company's collaboration with Tamar Innovest and supports its strategic goals.

Insights into Tamar Innovest's Stake

Tamar Innovest currently holds a significant share in Innocan, with ownership of 765,020 Common Shares, amounting to 17% of the company's total issued shares. Managing this entity is Ralph Bossino, who also serves on Innocan's board of directors. Given this relationship, Tamar Innovest's participation in the debenture offering qualifies as a related party transaction under the guidelines set by Multilateral Instrument 61-101. In light of this, Innocan has opted to adhere to specified exemptions from detailed valuation and minority approval requirements, as the offering does not exceed 25% of the company’s market capitalization.

The transaction has been reviewed and approved by independent directors within the company, further solidifying its integrity and compliance with regulatory standards.

About Innocan Pharma

Innocan Pharma is recognized for its innovative approaches within both the pharmaceutical and wellness industries. The company boasts a unique CBD-loaded liposome drug delivery platform that offers precise dosing and controlled release, aiming for effective non-opioid pain management solutions. In the wellness sector, Innocan markets an extensive array of self-care and beauty products, advocating for healthier lifestyles. Through its 60%-owned subsidiary, BI Sky Global Ltd., Innocan focuses on leveraging advanced online sales strategies.

For more information about Innocan and its offerings, interested parties can visit Innocan Pharma.

Looking Ahead

As Innocan Pharma prepares for growth, the newly acquired capital from this debenture is expected to play a crucial role in advancing its listings and enhancing corporate undertakings. This strategic alliance with Tamar Innovest underlines the firm's commitment to establishing a strong presence in the competitive pharmaceutical and wellness markets.

In conclusion, this debenture offering not only underscores Innocan's confidence in its operational strategies but also highlights the strong backing from its primary shareholder, setting the stage for greater achievements in the near future.